Blood | American Society of Hematology

Skip Nav Destination

Current Issue

Volume 144,

Issue 4,

July 25 2024

View This Issue

Issue Highlights

Variation in hematopoietic stem cell aging
MRD as intermediate clinical end point in myeloma
Loss of LGR6 disrupts human immune responses
Hereditary angioedema and venous thromboembolism
IPSS-R downstaging before transplant in MDS
Review: IL-1 and hematopoietic dysfunction in aging
Glofitamab in CNS lymphoma

Latest in Blood

Free Articles

Nonleukemic T/B mixed phenotype acute leukemia with PHF6 and NOTCH1 mutations

Oscar Silva; Allison Shaw

https://doi.org/10.1182/blood.2021012538

View All Free Articles

Plenary Papers

EVIDENCE meta-analysis: evaluating minimal residual disease as an intermediate clinical end point for multiple myeloma

Ola Landgren; Thomas J. Prior; Tara Masterson; Christoph Heuck; Orlando F. Bueno; Ajeeta B. Dash; Hermann Einsele; Hartmut Goldschmidt; Stefan Knop; Cong Li; Ulf-Henrik Mellqvist; Ian McFadden; Corina Oprea; Jeremy A. Ross; Mihaela Talpes; Jay R. Hydren; Jennifer M. Ahlstrom; Dickran Kazandjian; Niels Weinhold; Rick Zhang; Maryalice Stetler-Stevenson; Gerald Marti; Sean M. Devlin

https://doi.org/10.1182/blood.2024024371

View All Plenary Papers

First Edition

Treatment of Relapsed/Refractory MCL

Elisabeth Silkenstedt; Martin Dreyling

https://doi.org/10.1182/blood.2023022353

View All First Edition Articles

Clinical Trials and Observations

Treatment of Relapsed/Refractory MCL

Elisabeth Silkenstedt; Martin Dreyling

https://doi.org/10.1182/blood.2023022353

View All Clinical Trials and Observations

Advertisement intended for health care professionals

ASH Statement in Support of the Value of Scholarly Publishers

Acknowledgement of Reviewers

ASH Commitment to Diversity, Equity, and Inclusion in Health Care

Issue Highlights

Featured Content

Impact of MRD-negative on PFS in myeloma; IPSS-R down-staging before transplant in MDS; hereditary angioedema and venous thromboembolism

EVIDENCE meta-analysis: evaluating minimal residual disease as an intermediate clinical end point for multiple myeloma

Does IPSS-R downstaging before transplantation improve the prognosis of patients with myelodysplastic neoplasms?

Increased risk of venous thromboembolism in young and middle-aged individuals with hereditary angioedema: a family study

Variation in mesenchymal KITL/SCF and IGF1 expression in middle age underlies steady-state hematopoietic stem cell aging

An LGR6 frameshift variant abrogates receptor expression on select leukocyte subsets and is associated with viral infections

ASH Publications

American Society of Hematology

Issue Highlights

Featured Content

Impact of MRD-negative on PFS in myeloma; IPSS-R down-staging before transplant in MDS; hereditary angioedema and venous thromboembolism

EVIDENCE meta-analysis: evaluating minimal residual disease as an intermediate clinical end point for multiple myeloma

Does IPSS-R downstaging before transplantation improve the prognosis of patients with myelodysplastic neoplasms?

Increased risk of venous thromboembolism in young and middle-aged individuals with hereditary angioedema: a family study

Variation in mesenchymal KITL/SCF and IGF1 expression in middle age underlies steady-state hematopoietic stem cell aging

An LGR6 frameshift variant abrogates receptor expression on select leukocyte subsets and is associated with viral infections

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only